European Hub for Advanced Development in Regenerative Medicine and Biomaterials (EHAB)
Das Projekt European Hub for Advanced Development in Regenerative Medicine and Biomaterials (EHAB) startete am 1. Dezember 2023 und ist mit einer Laufzeit bis zum 30. November 2024 geplant. Für das Projekt stehen insgesamt 499.210 Euro zur Verfügung. In die BioRegion STERN fließen davon 59.820 Euro, von denen 100 Prozent gefördert werden.
Die folgenden Informationen liegen ausschließlich in englischer Sprache vor.
EHAB Mission
EHAB’s mission is to identify regional strengths, weaknesses, gaps and needs in a consolidated transregional Advanced Therapies and Biomaterials (AT&B) value chain and to elaborate a joint action plan to strengthen the performance and capacity of the innovation ecosystems of e.g. SME’s innovation stakeholders and their efficient interconnections ant their alignment towards EU-level priorities, jointly tackling challenges at EU, national, regional, and local level together with all the quadruple helix stakeholders.
Participants EHAB
- Brabant Development Agency (BOM), The Netherlands)
- Brightlands Biomedical Ecosystem represented by Brightlands Maastricht Health Campus, The Netherlands
- FlandersBio, Belgium
- BioRegio STERN, Germany
- A4tec-association (A4TEC), Portugal
- BIOCAT, Spain
- Resarch Institutes of Sweden AB (RISE), Sweden
- MedSilesia, Gornslaski Akcelerator Przedsiebiorczosci Rynkowej sp z o.o. (GAPR), Poland
EHAB is endorsed by several regional and European level organisations, including : the Province of North-Brabant, the Province of Limburg, the RegMed XB consortium, the department of Economy, Science and Innovation of the Flemish Government, the Smart Health Pilot of the Vanguard Initiative, the Health Department from the Generalitat de Catalunya, Leitat, ASEBIO, the Vall d’Hebron Institute of Oncology, the Fraunhofer-Institut für Produktionstechnik und Automatisierung (Fraunhofer IPA), and the Marshall Office of the Silesia Voivodeship.